ENZO BIOCHEM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 USD | 0.00% |
|
0.00% | -21.58% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the Enzo Biochem Third Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
Calendar
2024-06-09
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -21.58% | 55.84M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +43.45% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- ENZ Stock
- News Enzo Biochem, Inc.
- Transcript : Enzo Biochem, Inc., Q3 2021 Earnings Call, Jun 09, 2021
